首页|First-in-human safety, tolerability, and pharmacokinetics of ammoxetine in healthy subjects: a randomized, double-blind, placebo-controlled phase I study

First-in-human safety, tolerability, and pharmacokinetics of ammoxetine in healthy subjects: a randomized, double-blind, placebo-controlled phase I study

扫码查看
原文链接
  • NSTL
  • Elsevier
Background: : Ammoxetine is a novel selective serotonin and norepinephrine reuptake inhibitor. Preclinical studies have indicated the potential utility of ammoxetine for therapy in major depressive disorder.

AmmoxetineMajor depressive disorderFirst-in-humanPharmacokinetics

Shen, Qi、Hu, Chao、Miao, Jia、Chen, Junxia、Peng, Yueying、Pan, Tingting、He, Xiaolin、Yuan, Jing、Ni, Shaonan、Wang, Yongsheng、Luo, Zhu

展开 >

Sichuan Univ, West China Hosp, Inst Drug Clin Trials, GCP Ctr, 37 Guoxue Lane, Chengdu 610044

CSPC Zhongqi Pharmaceut Technol Shijiazhuang Co L, Dept Med, Shijiazhuang, Hebei, Peoples R China

CSPC Zhongqi Pharmaceut Technol Shijiazhuang Co L, Dept Project Management, Shijiazhuang, Hebei

CSPC Zhongqi Pharmaceut Technol Shijiazhuang Co L, Dept Biostat, Shijiazhuang, Hebei, Peoples R

展开 >

2021

10.1016/j.ejps.2021.105724

European journal of pharmaceutical sciences

European journal of pharmaceutical sciences

ISTP
ISSN：0928-0987
年,卷(期)：2021.159
  • 1
  • 30